Vaccines

Antibody “fingerprinting” method potential advance to slow spread of dengue

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

Bivalent booster vaccine effective in preventing COVID-19 hospitalization in older adults

The new bivalent mRNA COVID-19 booster vaccines that began being used in September are beneficial in preventing COVID-19-associated hospitalization in persons 65 and over.

Year in Review 2022: Achievements, milestones abounded during the past year

The following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2022.

VUMC in the news, Nov. 22, 2022

Several from VUMC among most highly cited researchers

Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17

On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.

1 2 3 4 5 15